Clôture précédente | 1,1100 |
Ouverture | 1,1000 |
Offre | 0,0000 x 0 |
Vente | 0,0000 x 0 |
Var. jour | 1,0994 - 1,1000 |
Sur 52 semaines | 1,0994 - 1,1000 |
Volume | |
Volume moyen | S.O. |
Cap. boursière | S.O. |
Bêta (mensuel sur 5 ans) | 0,95 |
Rapport P/E (sur 12 mois) | S.O. |
BPA (sur 12 mois) | S.O. |
Date de bénéfices | S.O. |
Dividende et rendement à terme | S.O. (S.O.) |
Date ex-dividende | S.O. |
Objectif sur 1 an | S.O. |
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,